Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

TAB006 · CHS-006, JS006

Monoclonal antibody · Antagonist of TIGIT

Phase 1 Most advanced trial (none active)
1 Registered trials

What is TAB006?

TAB006 is a humanized IgG4 monoclonal antibody that binds TIGIT, an immune checkpoint inhibitor on tumor-infiltrating lymphocytes and other immune cells. By blocking TIGIT, it prevents inhibitory signaling and enhances CD226-mediated costimulatory signaling, activating T-cell and NK-cell responses against cancer. It is studied in advanced solid tumors, non-small cell lung cancer, and hepatocellular carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CHS-006, JS006
Drug type
Monoclonal antibody
Targets
TIGIT, CD112 (NECTIN2) (secondary target), CD155 (PVR) (secondary target), CD226 (secondary target)
Mechanism
Antagonist of TIGIT
Pathways
immune activation, T-cell proliferation and activation
Therapy area
Oncology
In trials of
MEDP
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05757492 Phase 1 Advanced Solid Tumor Terminated MEDP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorHepatocellular CarcinomaNon-Small Cell Lung Cancer

Other drugs acting on TIGIT

BMS-986442 Phase 1 Dargistotug Phase 2 Domvanalimab Phase 2 Rilvegostomig Phase 3 Tiragolumab Phase 1/2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.